PTLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Portola Pharmaceuticals has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Portola Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 was -221.45%. As of today, Portola Pharmaceuticals's Piotroski F-Score is 0.
For the Biotechnology subindustry, Portola Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Portola Pharmaceuticals's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Portola Pharmaceuticals has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Portola Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2020 ) | / | Revenue (Q: Mar. 2020 ) |
= | -58.438 | / | 26.389 | |
= | -221.45 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Portola Pharmaceuticals has an F-score of 0. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Portola Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Dennis M Fenton | director | |
John B Moriarty | officer: EVP, General Counsel | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Hollings Renton | director | |
David C Stump | director | |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Jeffrey W Bird | director | 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005 |
Henry Ward Wolff | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
J. Scott Garland | director, officer: President and CEO | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Mardi Dier | officer: EVP and CFO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Rajiv Patni | officer: EVP, CMO | C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
John T Curnutte | officer: EVP R&D | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Charles J Homcy | other: Former Director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
William Lis | director, officer: Chief Executive Officer | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired Marketwired • 03-09-2020
By Marketwired Marketwired • 03-12-2020
By PRNewswire PRNewswire • 05-06-2020
By Marketwired Marketwired • 03-12-2020
By PRNewswire PRNewswire • 05-05-2020
By Marketwired Marketwired • 03-04-2020
By Marketwired Marketwired • 03-07-2020
By PRNewswire PRNewswire • 04-24-2020
By Marketwired Marketwired • 03-08-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.